We develop transformative medicines and technologies by building agile, focused companies called Vants.
Roivant was founded in 2014 with the aim to improve the lives of patients by accelerating the development and commercialization of medicines that matter.
01
Roivant builds nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies
Our Vants have conducted 10 positive Phase 3 trials since 2019, and launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults
02
1 Successful Commercial Launch
In 2022, we launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults. Organon acquired Dermavant in 2024
03
Diverse leadership and employee base
We have worked to ensure an open, diverse, and inclusive culture, while building a leadership team, board of directors and broader employee base that reflects these values.
Our vant creation Process:
The Roivant Model
Learn more about our work
Sign up for our latest announcements and upcoming presentations
Advancing medicines that matter
View our broad and differentiated pipeline of investigational drugs.